By Professor Michael Leonard Friedlander

Conference Abstracts

Friedlander M; Benson C; O'Connell RL; Reed N; Clamp A; Lord R; Millan D; Nottley S; Amant F; Steer C; Anand A; Mileshkin L; Beale P; Banerjee S; Bradshaw N; Kelly C; Carty K; Divers L; Alexander L; Edmondson R, 2021, 'Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903)', in Gynecologic Oncology, Vol. 161, pp. 160 - 165, http://dx.doi.org/10.1016/j.ygyno.2021.02.016

Sivakumaran T; Krasovitsky M; Freimund A; Lee KC; Webber K; So J; Norris C; Friedlander M; Mileshkin L; Au-Yeung G, 2020, 'TREATMENT PATTERNS POST PARP INHIBITOR IN EPITHELIAL OVARIAN CANCER PATIENTS: RESULTS FROM AN AUSTRALIAN, RETROSPECTIVE, MULTI-INSTITUTE COHORT STUDY', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, Vol. 30, pp. A166 - A167, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000616549600346&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

O'Malley DM; Bookman MA; Moore KN; Fleming GF; Brady MF; Swisher EM; Aghajanian C; Steffensen KD; Friedlander M; Okamoto A; Spirtos NM; Shahin MS; Reid TJ; Sullivan DM; Sehgal V; Ansell PJ; Dinh MH; Coleman RL, 2020, 'Anti-tumor activity of veliparib during combination phase with chemotherapy in velia study', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, Vol. 159, pp. 52 - 53, http://dx.doi.org/10.1016/j.ygyno.2020.06.110

Kaufman B; Han H; Arun B; Wildiers H; Friedlander M; Ayoub J-P; Puhalla S; Maag D; Feng D; Fages S; Dieras VC, 2020, 'Characteristics of patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer who achieved durable response in the phase III BROCADE3 study', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 31, pp. S374 - S374, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.427

Dieras V; Arun B; Han HS; Wildiers H; Friedlander M; Ayoub JP; Puhalla S; Hudgens S; Floden L; Khandelwal N; Benjamin K; Kamalakar R; Maag D, 2020, 'Health-related quality of life (HRQoL) changes with veliparib in patients (pts) with metastatic or locally advanced breast cancer in the phase III BROCADE 3 study', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 31, pp. S348 - S349, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.376

Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon T-W; Sonke GS; Lisyanskaya AS; Kim J-H; Abdo Filho E; Vergote I; Rowe P; Pujade-Lauraine E, 2020, 'Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302431&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Aghajanian C; Bookman MA; Fleming GF; Brady MF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Moore KN; Sullivan DM; Fallstrom M; Dinh M; Ratajczak C; Coleman RL, 2020, 'PFS by blinded independent central review (BICR) in the VELIA trial of veliparib (V) plus carboplatin/paclitaxel (CP) and as monotherapy in newly diagnosed patients (pts) with high-grade serous ovarian cancer (HGSC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302501&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Han HS; Arun B; Kaufman B; Wildiers H; Friedlander M; Ayoub J-PM; Puhalla SL; Bach BA; Dudley M; Kundu MG; Maag D; Ratajczak C; Dieras V, 2020, 'Veliparib (V) monotherapy (monoTx) following combination therapy with V plus carboplatin/paclitaxel (CP) in patients with gBRCA-associated advanced breast cancer: Exploratory results from BROCADE3.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368300309&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Puhalla SL; Dieras V; Arun B; Kaufman B; Wildiers H; Han HS; Ayoub J-PM; Stearns V; Yuan Y; Helsten TL; Riley-Gillis B; Murphy E; Kundu MG; Wu M; Maag D; Ratajczak C; Ramathal C; Friedlander M, 2020, 'Veliparib (V) monotherapy after progression on placebo (PL) plus carboplatin/paclitaxel (CP) in patients with advanced HER2-negative gBRCA-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368300315&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Jones T; Spence R; Sandler C; Obermair A; Friedlander M; Mileshkin L; Davis A; Janda M; Eakin E; Barnes E; Beesley V; Gordon L; Brand A; Hayes S, 2020, 'Are The ACSM Exercise Guidelines Safe And Achievable For Women Receiving Chemotherapy For Ovarian Cancer?', in MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 52, pp. 483 - 484, presented at American-College-of-Sports-Medicine (ACSM) Virtual Conference, ELECTR NETWORK, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000590026301686&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Li T; Timmins H; McCrary J; Trinh T; Friedlander M; Horvath L; Kiernan M; Goldstein D; Park S, 2020, 'Patient reported outcome scores used in chemotherapy-induced peripheral neuropathy: Defining minimal important differences', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, ELECTR NETWORK, Vol. 25, pp. 481 - 481, presented at Virtual Conference of Peripheral-Nerve-Society, ELECTR NETWORK, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000596008100112&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander ML; Hettle R; Parkhomenko E, 2019, 'Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SINGAPORE, Singapore, Vol. 30, presented at European-Society-for-Medical-Oncology (ESMO) Asia Congress, SINGAPORE, Singapore, 22 November 2019 - 24 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000503487700218&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander ML; Moore KN; Colombo N; Scambia G; Kim B-G; Oaknin A; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; Gonzalez-Martin A; Aghajanian C; Bradley W; Lowe E; Hettle R; Flood E; Disilvestro P, 2019, 'Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SINGAPORE, Singapore, Vol. 30, presented at European-Society-for-Medical-Oncology (ESMO) Asia Congress, SINGAPORE, Singapore, 22 November 2019 - 24 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000503487700217&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Antill Y; Kok PS; Stockler MR; Robledo K; Yip S; Parry M; Smith D; Spurdle A; Barnes E; Friedlander ML; Baron-Hay S; Shannon C; Coward J; Beale J; Goss G; Meniawy T; Andrews J; Kelly M; Mileshkin L, 2019, 'Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SINGAPORE, Singapore, Vol. 30, presented at European-Society-for-Medical-Oncology (ESMO) Asia Congress, SINGAPORE, Singapore, 22 November 2019 - 24 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000503487700534&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Beesley VL; Ross TL; Na NR; Sivakumaran T; Au-Yeung G; Nagle CM; deFazio A; Grant P; Obermair A; Friedlander M; Webb P, 2019, 'Does physical activity improve chemotherapy completion in women receiving chemotherapy for ovarian cancer?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 82 - 83, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mizrahi D; Trinh T; Au K; Timmins HC; Li T; McCrary JM; Friedlander M; Grimison P; Park SB; Goldstein D, 2019, 'Does physical activity participation associate with the degree of chemotherapy-induced peripheral neuropathy after neurotoxic treatment?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 179 - 179, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400288&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Scott C; Lee CK; Lee YC; Friedlander M; Hollis S; Diamante K; Davies C; Stockler M; Plebanski M, 2019, 'SOLACE2: A phase II randomised trial of immune priming by olaparib-cyclophosphamide prior to olaparib-durvalumab in asymptomatic, platinum-sensitive recurrent ovarian cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 160 - 161, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400250&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander ML; Moore K; Colombo N; Scambia G; Kim B-G; Oaknin A; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; Gonzalez-Martin A; Aghajanian C; Bradley W; Lowe E; Hettle R; Flood E; DiSilvestro P, 2019, 'Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295503045&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dieras VC; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub J-P; Puhalla SL; Bondarenko I; Campone M; Jakobsen EH; Jalving M; Oprean C; Palacova M; Park YH; Shparyk Y; Yanez E; Dudley M; Ratajczak CK; Maag D; Arun BK, 2019, 'Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 857 - +, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295500133&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Oaknin A; Moore K; Colombo N; Scambia G; Kim B-G; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza AM; Gonzalez-Martin A; Aghajanian C; Bradley W; Lowe ES; Bloomfield R; DiSilvestro P, 2019, 'Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 405 - 405, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295503044&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kok PS; Yoon W-H; Marschner I; Lord SJ; Friedlander M; Lee CK, 2019, 'Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 520 - 520, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295503324&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Coleman RL; Fleming GF; Brady MF; Swisher E; Steffensen KD; Friedlander M; Okamoto A; Moore K; Ben-Baruch N; Werner TL; Oaknin A; Nam J-H; Leath CA; Nicum S; Cella D; Sullivan DM; Ansell PJ; Dinh M; Aghajanian C; Bookman MA, 2019, 'VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 895 - 896, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295500127&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Poveda A; Sackeyfio A; Friedlander M, 2019, 'MAINTENANCE OLAPARIB FOR BRCA-MUTATED OVARIAN CANCER (OC) PATIENTS IN 1ST LINE AND PLATINUM-SENSITIVE RELAPSED (PSR) SETTINGS: MAXIMIZING TREATMENT OPPORTUNITIES', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, Vol. 29, pp. A133 - A133, http://dx.doi.org/10.1136/ijgc-2019-IGCS.321

Antill YC; Kok PS; Robledo K; Barnes E; Friedlander M; Baron-Hay SE; Shannon CM; Coward J; Beale PJ; Goss G; Meniawy T; Yip S; Smith D; Spurdle AB; Parry M; Andrews J; Kelly M; Stockler MR; Mileshkin LR, 2019, 'Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5501

Colombo N; Moore KN; Scambia G; Oaknin A; Friedlander M; Lisyanskaya AS; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee SN; Oza AM; Gonzalez-Martin A; Aghajanian C; Bradley WH; Kim J-W; Lowe ES; Bloomfield R; Disilvestro P, 2019, 'Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5539

Friedlander M; Moore KN; Colombo N; Scambia G; Kim B-G; Oaknin A; Lisyanskaya AS; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee SN; Oza AM; Gonzalez-Martin A; Aghajanian C; Bradley WH; Lowe ES; Bloomfield R; Disilvestro P, 2019, 'Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5551

Roncolato F; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan PP; Oza AM; Avall-Lundqvist E; Berek JS; Sehouli J; Ledermann JA; Berton-Rigaud D; Kiely BE; Friedlander M; Stockler MR, 2019, 'How long have we got? The accuracy of physicians' estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5549

Mathews CA; Moore KN; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya AS; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee SN; Oza AM; Gonzalez-Martin A; Aghajanian C; Bradley WH; Lowe ES; Bloomfield R; Disilvestro P, 2019, 'Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5541

Desai J; Markman B; Friedlander M; Gan H; Horvath L; Townsend A; Millward M; Jameson M; Yen C-J; Hou M-M; Hou J; Wu J; Liang L; Deva S, 2019, 'Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-CT084

Sackeyfio A; Santi I; Friedlander M, 2018, 'EXPLORING THE IMPACT OF RADIOGRAPHIC PROGRESSIVE DISEASE AND FIRST SUBSEQUENT THERAPY ON HEALTH STATE UTILITY VALUES IN GERMLINE-BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSROC) PATIENTS ON OLAPARIB TABLETS AS MAINTENANCE MONOTHERAPY', in VALUE IN HEALTH, ELSEVIER SCIENCE INC, Vol. 21, pp. S73 - S73, http://dx.doi.org/10.1016/j.jval.2018.09.429

Peate M; Jayasinghe Y; Gamage NR; Allingham C; Meiser B; Friedlander M; Hickey M, 2018, 'From development to implementation: The Australian experience of oncofertility decision aids', in PSYCHO-ONCOLOGY, WILEY, Vol. 27, pp. 44 - 45, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000448188000113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Peate M; Patterson T; Girgis A; Friedlander M; Durcinoska I; Hickey M; Sousa MS, 2018, 'Genitourinary and sexual health after breast cancer: The role of breast care nurses in providing support and care', in PSYCHO-ONCOLOGY, WILEY, Vol. 27, pp. 184 - 185, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000448188000492&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Oza AM; Cibula D; Oaknin A; Poole C; Mathijssen RHJ; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Pfisterer J; Plante M; Hanker LC; Fielding A; Haddad V; Chmielecki J; Friedlander M, 2018, 'Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy', in Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii340, http://dx.doi.org/10.1093/annonc/mdy285.158

Beesley VL; Webber K; Nagle C; Grant P; DeFazio A; Obermair A; Friedlander M; Webb PM, 2018, 'When will i feel normal again? Exploring the trajectories and predictors of patient-reported outcomes after completion of primary therapy for ovarian cancer', in PSYCHO-ONCOLOGY, WILEY, Vol. 27, pp. 50 - 50, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000448188000128&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Piskorz A; Robertson D; Lin KK; Morris J; Mann E; Oza A; Coleman RL; O'Malley DM; Friedlander M; Cragun JM; Ma L; Giordano H; McNeish IA; Swisher E; Wason J; Brenton JD, 2018, 'CTDNA RESPONSE TO THE PARP INHIBITOR RUCAPARIB PREDICTS PROGRESSION-FREE SURVIVAL AND BEST OVERALL RESPONSE ON THE ARIEL2 TRIAL', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, WA, Seattle, Vol. 25, pp. 112 - 112, presented at 12th Rivkin-Centre Biennial Ovarian Cancer Research Symposium, WA, Seattle, 13 September 2018 - 15 September 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000497337700065&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander M; Scott CL; Lindeman GJ; Gibbs E; Badger HD; Paterson RJ; Macnab L; Zdenkowski N; Kwan EM; Boyle FM; Lee CK, 2018, 'A Phase 1 Trial of Olaparib and Oral Metronomic. Cyclophosphamide in Patients with Metastatic BRCA-Associated Breast/Ovarian Cancers or Non-BRCA Associated Triple-Negative Breast Cancer/High Grade Serous Ovarian Cancers', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 59 - 59, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439493100024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander M; Meniawy T; Markman B; Mileshkin LR; Harnett P; Millward M; Lundy J; Freimund AE; Norris C; Wu J; Paton V; Wang L; Gao B, 2018, 'A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 58 - 59, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439493100023&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hasenburg A; Harter P; Park-Simon T-W; Gropp-Meier M; Heitz F; Soergel P; Ataseven B; Friedlaender M; Hilpert F; Pujade-Lauraine E, 2018, 'Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer: SOLO2 Phase III', in ONCOLOGY RESEARCH AND TREATMENT, KARGER, Vol. 41, pp. 88 - 89, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424914300235&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander M; Gourley C; Matulonis U; Shirinkin V; Selle F; Scott C; Safra T; Fielding A; Rowe P; Ledermann JA, 2017, 'CLINICALLY SIGNIFICANT LONG-TERM MAINTENANCE TREATMENT WITH OLAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, Vol. 27, pp. 1942 - 1943, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000423235205226&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander M; Gebski V; Gibbs E; Bloomfield R; Hilpert F; Wenzel LB; Joly F; Eek D; Rodrigues M; Clamp A; Penson R; Provencher D; Korach J; Huzarski T; Vidal L; Salutari V; Scott C; Nicoletto MO; Tamura K; Pujade-Lauraine E, 2017, 'HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND PATIENT-CENTRED OUTCOMES WITH OLAPARIB MAINTENANCE POST-CHEMOTHERAPY IN PATIENTS WITH GERMLINE BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, Vol. 27, pp. 1941 - 1941, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000423235205225&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Meagher NS; deFazio A; Russell K; Voss A; Ramus SJ; Friedlander ML, 2017, 'Mucinous Ovarian Cancers of Uncertain Primary (MO-CUP) - Does the Site of Origin Really Matter?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 13, pp. 73 - 73, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hettle R; Sackeyfio A; Gill J; Siddiqui K; Nussey F; Friedlander M, 2017, 'COMPARATIVE EFFICACY AND SAFETY OF OLAPARIB 300 MG TABLETS BID AND NIRAPARIB 300 MG TABLETS QD AS MAINTENANCE TREATMENT AFTER RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED GERMLINE BRCA-MUTATED OVARIAN CANCER (PSROC)', in VALUE IN HEALTH, ELSEVIER SCIENCE INC, Vol. 20, pp. A412 - A412, http://dx.doi.org/10.1016/j.jval.2017.08.088

Sackeyfio A; Gill J; Hettle R; Siddiqui K; Friedlander M; Ledermann JA, 2017, 'COMPARATIVE EFFICACY AND SAFETY OF OLAPARIB 400 MG CAPSULES BID AND NIRAPARIB 300 MG TABLETS QD AS MAINTENANCE TREATMENT AFTER RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED NON-GERMLINE BRCA-MUTATED OVARIAN CANCER (PSROC)', in VALUE IN HEALTH, ELSEVIER SCIENCE INC, Vol. 20, pp. A412 - A412, http://dx.doi.org/10.1016/j.jval.2017.08.087

Webber K; Girgis A; Kaye B; Bonaventura BA; Boyle FM; Koh E-S; Friedlander M; Segelov E; Goldstein D, 2013, 'The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 31, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419603085&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Webber K; Girgis A; Bennett BK; Bonaventura T; Boyle F; Koh E-S; Friedlander M; Segelov E; Goldstein D, 2012, 'CURRENT CARE AND NEEDS OF ADULT CANCER SURVIVORS - A CROSS-SECTIONAL SURVEY', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, Vol. 8, pp. 356 - 357, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000310544400419&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mok K; Mireskandari S; Juraskova I; Jarvis S; Friedlander M, 2006, 'OVER (Olive oil Vaginal Exercises and Replens) come', in PSYCHO-ONCOLOGY, WILEY-BLACKWELL, Vol. 15, pp. S332 - S332, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000242413901224&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Tiller K; Meiser B; Tucker K; Andrews L; Gaff C; Kirk J; Phillips KA; Duding T; Friedlander M, 2003, 'A randomised trial of a decision aid for women at risk for ovarian cancer', in PSYCHO-ONCOLOGY, JOHN WILEY & SONS LTD, Vol. 12, pp. S107 - S107, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000183225400100&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Preprints

Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan MC; Barnes EH; Goldstein D; Park SB, 2024, Peripheral Neuropathy in Cancer Patients- Multifactorial Contributors to Dose Limiting and Chronic Toxicity, http://dx.doi.org/10.1101/2024.07.24.24310956

Other

Macdonald C; Saunders CM; Keogh LA; Hunter M; Mazza D; McLachlan S-A; Jones SC; Nesci S; Friedlander ML; Hopper JL; Emery JD; Hickey M; Milne RL; Phillips K-A, 2023, Data from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, http://dx.doi.org/10.1158/1940-6207.c.6547304.v1

Macdonald C; Saunders CM; Keogh LA; Hunter M; Mazza D; McLachlan S-A; Jones SC; Nesci S; Friedlander ML; Hopper JL; Emery JD; Hickey M; Milne RL; Phillips K-A, 2023, Data from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, http://dx.doi.org/10.1158/1940-6207.c.6547304

Back to profile page